Should You Buy Aptargroup Inc (ATR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
124.950
1 Day change
0.89%
52 Week Range
164.280
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner, long-term investor who wants to enter immediately. ATR looks fundamentally solid, but the near-term setup is muted (multiple recent downgrades/price-target cuts, limited catalysts, and options positioning leaning defensive). If you already own it, holding into the next earnings (2026-02-05) is reasonable; if you don’t own it, this is not an attractive “buy-now” entry based on today’s data.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Technical Analysis
Pre-market price ~$124.74 is essentially sitting on the pivot (124.94), reflecting a neutral/indecisive tape.
- Trend/Momentum: MACD histogram is positive (0.121) but *contracting*, suggesting upside momentum is fading rather than accelerating.
- RSI(6): ~49.7 (neutral), no oversold/overbought edge for an impatient entry.
- Moving averages: Converging MAs typically imply consolidation/sideways price action rather than a clean uptrend.
- Key levels: Support S1=123.15 then S2=122.05. Resistance R1=126.73 then R2=127.83. With price near pivot, risk/reward is not compelling unless you have a catalyst.
- Pattern-based projection: Similar-pattern stats indicate a mild bearish bias near-term (-0.45% next day, -1.57% next week), with a better 1-month skew (+3.21%), consistent with “choppy now, potentially better later.”
Options Data
Bearish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio
Options sentiment is cautious-to-neutral with elevated risk pricing:
- Put/Call (Open Interest) = 1.34: more outstanding puts than calls, signaling more hedging/defensive positioning.
- Put/Call (Volume) = 0.95: today’s trading is close to balanced, not an outright panic.
- Volatility: IV(30d) ~30.78 vs HV ~26.14, and IV percentile ~90.8 (rich). Options are pricing elevated uncertainty; that often coincides with investor caution ahead of catalysts.
- Activity: today’s volume is ~354.6% of the 30-day average, suggesting a sentiment/positioning event, but direction is not strongly bullish given the higher put open interest.
Technical Summary
Sell
4
Buy
10
Positive Catalysts
Long-term positioning in Pharma dispensing remains a positive recurring theme from analysts.
Next earnings: QDEC 2025 earnings on 2026-02-05 (after hours) can reset expectations if guidance improves.
Latest reported quarter (2025/Q
showed strong EPS and net income growth, which can support long-term confidence if margin stabilizes.
Neutral/Negative Catalysts
No news catalysts in the last week; the market currently lacks a clear rebound trigger.
Analysts cite muted growth over the next several quarters and pressure from product/mix dynamics (including emergency medicine dispensing normalization) and weaker areas (beauty/closures, China).
Near-term technicals are neutral (not oversold), reducing the appeal of an “impatient” buy-the-dip entry.
Financial Performance
Latest quarter: 2025/Q3.
- Revenue: $961.13M, +5.70% YoY (steady growth).
- Net Income: $127.93M, +27.88% YoY (strong profitability growth).
- EPS: $1.92, +29.73% YoY (strong per-share growth).
- Gross Margin: 29.95%, down ~4.04% YoY (margin compression is the main blemish and aligns with analyst concerns about mix/profit trend).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: ratings and price targets have moved *down* overall, indicating cooling Street confidence in the near-term.
- 2026-01-06: Wells Fargo downgraded to Equal Weight (from Overweight), PT $133; cited lack of catalysts and sluggish fundamentals.
- 2026-01-05: BofA kept Neutral, cut PT to $142 (from $158); likes long-term pharma positioning but sees intermediate headwinds.
- 2025-11-03: Baird kept Outperform, cut PT to $145 (from $160); long-term story intact.
- 2025-11-01: William Blair downgraded to Market Perform; expects muted growth/profit pressure for several quarters.
Wall Street pros view (pros): strong long-term pharma dispensing franchise, Q3 EPS strength, durable business.
Wall Street cons view (cons): catalyst gap, near-term growth/profit headwinds, mix shift and normalization issues, some segment weakness (Beauty/China), and a more challenging multi-quarter setup.
Influential trading check:
- Hedge funds: Neutral (no significant recent trend).
- Insiders: Neutral (no significant recent trend).
- Congress trading (last 90 days): No recent data available.
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 148 USD with a low forecast of 133 USD and a high forecast of 172 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 148 USD with a low forecast of 133 USD and a high forecast of 172 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 123.850
Low
133
Averages
148
High
172
Current: 123.850
Low
133
Averages
148
High
172
Wells Fargo
Overweight -> Equal Weight
downgrade
$133
AI Analysis
2026-01-06
Reason
Wells Fargo
Price Target
$133
AI Analysis
2026-01-06
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded AptarGroup to Equal Weight from Overweight with a $133 price target. The firm says that while 2025 turned into a more challenging year than it originally expected, Wells is still waiting for a catalyst that will drive a rebound. K-shaped economy remains the firm's top concern as low-end consumer health remains poor. For AptarGroup, Wells sees lack of catalysts to outrun sluggish start of year fundamentals.
BofA
George Staphos
Neutral
downgrade
$158 -> $142
2026-01-05
Reason
BofA
George Staphos
Price Target
$158 -> $142
2026-01-05
downgrade
Neutral
Reason
BofA analyst George Staphos lowered the firm's price target on AptarGroup to $142 from $158 and keeps a Neutral rating on the shares. The firm likes Aptar over the long term, given solid positioning in Pharma dispensing. That said, earnings trends could be impacted in the intermediate term by the slowdown in emergency medicine dispensing, litigation, continued weakness in China, and the sluggish profit trend in Beauty, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATR
